| Code | CSB-RA004847MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LM-108, targeting C-C chemokine receptor 8 (CCR8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a critical role in immune cell trafficking and localization within tissues. This receptor is particularly enriched on tumor-infiltrating Tregs in various solid tumors, where it contributes to immunosuppressive microenvironments that facilitate tumor immune evasion. CCR8 expression has been implicated in multiple cancers including colorectal, breast, and non-small cell lung cancer, as well as in inflammatory conditions and allergic diseases.
LM-108 is a reference antibody designed to selectively target CCR8-expressing cells and has been investigated for its potential to deplete immunosuppressive Tregs within the tumor microenvironment. This biosimilar provides researchers with a valuable tool for investigating CCR8 biology, Treg function, and immune regulation in cancer and inflammatory disease models. It supports studies exploring novel immunotherapeutic approaches and mechanisms of tumor immune resistance.
There are currently no reviews for this product.